Clinical Trial Detail

NCT ID NCT02795156
Title Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors SCRI Development Innovations, LLC
Indications

larynx cancer

lung non-small cell carcinoma

vestibule of mouth cancer

biliary tract cancer

pancreatic cancer

nasal cavity cancer

paranasal sinus cancer

gum cancer

tonsil cancer

lip cancer

liver cancer

gastroesophageal cancer

transitional cell carcinoma

salivary gland cancer

oropharynx cancer

nasopharynx carcinoma

oral cavity cancer

tongue cancer

Therapies

Cabozantinib

Afatinib

Regorafenib

Age Groups: adult senior

No variant requirements are available.